Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC).

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2016

Conditions

Metastatic Breast CancerPancreatic CancerMetastatic Colorectal Cancer

Interventions

DRUG

lurbinectedin (PM01183)

lurbinectedin (PM01183) 1 mg and 4 mg vials

DRUG

capecitabine

capecitabine 150 mg tablets

Trial Locations (2)

Brussels

Barcelona